Screening for cognitive toxicity of anticholinergic drugs

I. R. Katz, W. H. Greenberg, G. A. Barr, C. Garbarino, P. Buckley, D. Smith

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Impairment of memory by muscarinic anticholinergic drugs has been demonstrated with a variety of agents using both acute administration in normal volunteers and chronic treatment in patients. Cognitive toxicity must be considered in the evaluation of the risks versus the benefits of psychopharmacologic treatment. The relationship between serum levels of anticholinergic drugs measured by radioreceptor assay and performance on the Buschke Selective Reminding Test were investigated to develop strategies for identifying patients with drug-related cognitive impairment. The radioreceptor assay may be of value in screening for patients at high risk for cognitive toxicity. However, there appears to be no alternative to careful longitudinal evaluation of learning and memory in patients after appropriate trial modifications of their medication regimens to identify patients with drug-related impairment.

Original languageEnglish (US)
Pages (from-to)323-326
Number of pages4
JournalJournal of Clinical Psychiatry
Issue number8
StatePublished - Oct 31 1985

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Screening for cognitive toxicity of anticholinergic drugs'. Together they form a unique fingerprint.

Cite this